Prolia

Prolia (denosumab) is a biologic medication used to help strengthen bones and reduce the risk of fractures in people with certain bone-related conditions. It is commonly used for individuals with osteoporosis, particularly postmenopausal women and men at high risk of bone fractures. Prolia works by targeting a specific protein involved in bone breakdown, helping to maintain bone density and improve overall bone strength.
Denosumab, the active ingredient in Prolia, is a monoclonal antibody that inhibits RANK ligand (RANKL), a key factor responsible for the formation and activity of cells that break down bone. By blocking RANKL, Prolia slows bone loss and supports the natural process of bone rebuilding. This targeted mechanism makes it effective in reducing fractures of the spine, hip, and other bones.
Prolia is also used in people receiving certain cancer treatments that may weaken bones, as well as in cases of bone loss associated with hormonal therapy. It is administered as an injection under the skin at specific intervals, ensuring consistent support for bone health over time. Patients are often advised to maintain adequate calcium and vitamin D intake while using this therapy to support optimal results.
Common side effects may include joint or muscle discomfort, back pain, or mild skin reactions at the injection site. Less commonly, low calcium levels, infections, or jaw-related issues can occur, especially in individuals with existing risk factors. Regular medical monitoring helps ensure safe and effective use.
Overall, Prolia is a well-established option for managing bone loss and reducing fracture risk, offering long-term benefits for individuals who need effective bone-strengthening support.